# Sermorelin Research: Mechanism, Pharmacokinetics, and Trial Data > Sermorelin research summarized: the GHRH-receptor cascade, the ~10-12 minute half-life, the pediatric height-velocity and older-adult IGF-1 findings, reported side effects, and what the secretagogue trials do and do not show. Mechanism, pharmacokinetics, efficacy, and reported side effects — each figure carried back to its study, each gap left in plain view. ## In plain English This page collects the **sermorelin** studies. The short story: in children who could not make enough growth hormone, daily sermorelin sped up growth; in healthy older men, it pushed an age-faded GH/IGF-1 system back toward youthful numbers for two weeks. The peptide leaves the blood in about ten minutes, but the growth-hormone bump it causes lasts a few hours. The strongest evidence is decades old and is about children; the adult anti-aging story is thinner, and the studies say so. Below, every claim is tied to a named, dated paper. ## Sermorelin acetate: the salt form studied **Sermorelin acetate** is the form used in the literature — the GHRH(1-29) peptide prepared as its acetate salt, supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions degrade [1]. The acetate salt has its own identifiers (CAS 114466-38-5) distinct from the free peptide, and reconstituted material is typically refrigerated. This is the substance behind every figure on this page; "sermorelin" and "sermorelin acetate" refer to the same molecule in its salt form. ## The GHRH-receptor cascade Sermorelin's activity runs through one receptor and one signaling chain — the [sermorelin mechanism of action](/) set out in summary on the home page. It binds the GHRH receptor on anterior-pituitary somatotrophs, engaging the Gs / adenylate cyclase / cAMP / protein kinase A pathway, which raises cyclic AMP and drives both GH gene transcription and GH release [1]. Over time the receptor signaling also has a trophic effect — it supports the somatotroph cell population itself. The loop stays closed. Somatostatin and IGF-1 feedback remain intact, and GH autofeedback on the GHRH response — involving free fatty acids and somatostatin — has been demonstrated directly in humans [13]. This is why sermorelin produces pulsatile rather than continuous GH, and why pulsatile GHRH delivery preserved the GH response better than continuous infusion in normal men [12]. ## Sermorelin half-life and pharmacokinetics The **sermorelin half-life** is short. After intravenous administration, GHRH(1-29)NH2 is cleared from plasma on the order of 10-12 minutes [3]. In 30 healthy men, intravenous doses elicited GH release from as little as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg; despite the rapid clearance, serum growth hormone stayed elevated for about 3 hours after a single dose [3]. By the intranasal route, bioavailability was only about 3-5% — a figure that explains why oral and sublingual "sermorelin" products are widely criticized in research-user communities as ineffective, since peptides are degraded in the gut and absorbed poorly across mucosa [3]. The brevity of the native fragment is the reason longer-acting analogs exist. Incorporating D-Ala2 into GHRH(1-29)NH2 increased its half-life and decreased its metabolic clearance in normal men [7] — the structure-activity step that leads to the DAC-based analogs on the [sermorelin vs CJC-1295](/sermorelin-vs-cjc-1295) page. ## Does sermorelin work? What the trials show **Does sermorelin work?** In its best-evidenced setting, yes. In prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth, lifting first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, and it did so without excessive IGF-1 generation [1]. In aging research the signal is also real but narrower. In healthy older men (mean 68 years), 0.5 mg and 1 mg subcutaneously twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after high-dose treatment, their GH/IGF-1 parameters no longer differed from those of young men, with no effect on fasting glucose [2]. The downstream IGF-1 effect can be sizeable: in the SMART trial of a stabilized GHRH analog, IGF-1 rose by 117% within the physiologic range [6]. What "work" does not yet mean is a proven long-term adult anti-aging or body-composition benefit. Those outcomes are documented mainly for the related analog tesamorelin, and authorities have cautioned against extrapolating [5]. ## The GH/IGF-1 axis in aging and the brain The most striking recent data come from the GHRH-analog class as a whole. In a randomized, double-blind, placebo-controlled trial of 152 older adults — 66 of them with mild cognitive impairment — 20 weeks of a daily GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable effect on cognition (P=0.03), with the strongest signal in executive function (P=0.005), alongside a 117% IGF-1 rise and a 7.4% reduction in percent body fat [6]. This is the [GH/IGF-1 axis in aging](/research) studied directly: raising GH and IGF-1 through a GHRH analog produced measurable cognitive and body-composition changes in older adults. It is the clearest evidence that the axis sermorelin engages is biologically active in aging humans — while remaining a finding about tesamorelin, not a license to claim the same magnitude for sermorelin itself. ## Reported side effects in the sermorelin literature **Sermorelin side effects** reported in the trial literature were generally mild — injection-site reactions are the most common, and the older-men study found no change in fasting glucose [2]. Adverse events in the SMART trial of the related analog were likewise mild [6]. The honest caveats are about scope, not acute toxicity. Long-term safety data specifically for adult anti-aging use are limited, and the Annals editorial judged secretagogue use for aging "not yet ready for prime time" [5]. Because GH and IGF-1 are mitogenic, chronically elevating them is theorized to carry an oncologic consideration — a recognized point for any GH-axis intervention, even one that works through the body's own feedback-regulated pulsatile secretion. This site describes these findings; it gives no dosing instructions and makes no recommendation to self-administer. ## Sermorelin and testosterone: what the research does and does not show On **sermorelin testosterone** questions the literature is clear by what it omits. Sermorelin acts on the GH/IGF-1 somatotropic axis — the pituitary's growth-hormone cells — not on the hypothalamic-pituitary-gonadal axis that governs testosterone [1]. The published studies document GH and IGF-1 changes [2][3][6]; they do not report testosterone effects. Claims that sermorelin raises testosterone are therefore not supported by the GHRH(1-29) trial record presented here, and this brief frames the two axes as distinct rather than implying a crossover the data does not show. ## Regulatory and anti-doping status The regulatory history is often misstated, so state it precisely. Sermorelin **was** an FDA-approved prescription drug for the evaluation and treatment of growth hormone deficiency / short stature in children, and it was withdrawn from the US market in 2008 for commercial reasons — not for safety or efficacy problems. It is not a currently-marketed approved finished drug; it is now prepared by compounding pharmacies and treated as a long-standing Category 1 bulk drug substance under FDA's Section 503A framework, with final guidance in January 2025. It is not a controlled substance under the Controlled Substances Act. In sport, growth hormone secretagogues — including GHRH and its analogs — are prohibited by WADA under hormone and metabolic modulators (S2), and dedicated detection methods for GHRH analogs exist. The material discussed here is research-grade sermorelin supplied for laboratory study, not a compounded prescription or a finished medicine. --- A confidence-graded intelligence brief on the GHRH(1-29) secretagogue record — each figure scored against its study, the pediatric-growth evidence held apart from the limited adult anti-aging data and the formerly-approved-now-compounded status stated plainly; no clinic behind the console and nothing here dosed, prescribed, or sold.